Robert A. Mitchell, PhD
Research Program
Molecular Targets
Education B.S., University of Iowa, Iowa City, Immunology, 1989 Research and Professional Experience 1991-1992 1992-1994 1994-1998 1999-2001 2002-present 2002-2008 2002-present 2008-present 2008-present Selected Awards and Profressional Honors Member, Molecular Medicine Society Ad hoc reviewer, Molecular Medicine, Oncology, Journal of Histochemistry and Cytochemistry, Clinical Cancer Research, Journal of Infectious Diseases, Journal of Pathology
Ph.D., Albany Medical College, Albany, NY, Pathology, 1998
Postdoctoral Fellow, Picower Institute for Medical Research, Manhasset, NY, 1998-1999
1989-1991
Principal Research Assistant, University of Minnesota, Minneapolis, MN
Senior Research Assistant, Rockefeller University, New York, NY
Senior Research Associate, Picower Institute for Medical Research, Manhasset, NY
Graduate Student, Albany Medical College, Albany, NY
Senior Scientist, Picower Institute for Medical Research, Manhasset, NY
Assistant Professor of Medicine, Division of Medical Oncology/Hemotology, Department of Medicine, University of Louisville, Louisville, KY
Assistant Professor, Department of Biochemistry & Molecular Biology(secondary), University of Louisville, Louisville, KY
Member, James Graham Brown Cancer Center, University of Louisville, Louisville, KY
Associate Professor, Department of Medicine, University of Louisville, Louisville, KY
Associate Professor, Department of Biochemistry & Molecular Biology (secondary), University of Louisville, Louisville, KY
Member, American Association for the Advancement of Sciences
Research Interest
Robert A. Mitchell Ph.D, joined the James Graham Brown Cancer Center as an Assistant Professor in the Departments of Medicine and Biochemistry & Molecular Biology and as a member of the Molecular Targets Program in May of 2002. He received his Ph.D. in Experimental Pathology from Albany Medical College and his B.S. from the University of Iowa School of Medicine. Prior to joining the staff at the Brown Cancer Center, Dr. Mitchell was a Senior Scientist at the Picower Institute for Medical Research in New York. His research focuses on the investigation and discovery of lipid mediators and polypeptides as soluble tumor-promoting molecules. A good deal of Dr. Mitchell’s current research focuses on the pro-inflammatory cytokine, migration inhibitory factor (MIF) as it relates to non-immune cell cycle regulation, oncogenic transformation and in vivo carcinogenesis. Biochemical and cell biology studies designed to identify cell surface, cytosolic and nuclear effectors of MIF action constitute about half of his lab efforts. A smaller portion of the laboratory’s research effort is aimed at the investigation and discovery of immunologic and small molecule inhibitors of MIF in hopes of identifying novel cancer chemotherapeutic compounds. The remainder of Dr. Mitchell’s lab effort focuses on establishing in vivo models of tumorigenesis and investigating novel anti-tumor vaccination strategies.
Publications
Sampey AV, Hall PH, Mitchell RA, Metz CN, Morand EF. Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. Arthritis Rheum 44:1273-80, 2001
Senter PD, Al-Abed Y, Metz CN, Benigni F, Mitchell RA, Gartner CG, Nelson SD, Todaro GJ, Bucala R. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci USA 99:144-9, 2002
Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, Bucala R. MIF sustains macrophage pro-inflammatory function by inhibiting p53: Regulatory role in the innate immune response. Proc Natl Acad Sci USA 99:345-50, 2002
Dios A, Mitchell RA, Aljabari B, Lubetsky J, O'Connor KA, Liao H, Senter PD, Manogue KR, Lolis E, Metz CN, Bucala R, Callaway DJ, Al-Abed Y. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J Med Chem 45:2410-6, 2002
Lubetsky JB, Dios A, Han J, Aljabari B, Ruzsicska B, Mitchell RA, Lolis E, Al-Abed Y. The tautomerase activity of MIF is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 277:24976-82, 2002
Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell RA, Bucala R. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 62:5881-87, 2002
Liao H, Bucala R, Mitchell RA. Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF). J Biol Chem 278:76-81, 2003
Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H, Susarla S, Czura C, Mitchell RA, Chen G, Sama AE, Tracey KJ, Wang H. IFN-gamma induces high mobility group box 1 potein release partly through a TNF-dependent mechanism. J Immunol 170:3890-7, 2003
Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R. MIF signal transduction initiated by binding to CD74. J Exp Med <